Drug Trial Radar · NCT04668352
A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly
Last checked: Nov 19, 2026Latest source record: Jun 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,024
Actual
Start
Apr 15, 2019
Primary completion
Dec 2, 2019
Study completion Dec 2, 2019
Sponsor
- Lead sponsor
- Restorbio Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To determine if RTB101 as compared to placebo decreases the percentage of subjects with clinically symptomatic respiratory illness (with or without an associated laboratory-confirmed pathogen) through Week 16.
Conditions
- Respiratory Tract Infections
Interventions
DactolisibDrug
TORC1 inhibitor
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With Clinically Symptomatic Respiratory IllnessTime frame: Week 0-16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
P3 Research Ltd.
Wellington, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.